Acurx Pharmaceuticals, Inc. (ACXP) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
ACXP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ACXP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export ACXP earnings history in CSV or JSON format
Free sign-in required to download data
Acurx Pharmaceuticals, Inc. (ACXP) Earnings Overview
As of May 8, 2026, Acurx Pharmaceuticals, Inc. (ACXP) reported trailing twelve-month net income of -$7.97B, reflecting +69.8% year-over-year growth. The company earned $-5314.57 per diluted share over the past four quarters.
Looking at the long-term picture, ACXP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2020.
Acurx Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ACIU (-$70M net income, -1971.6% margin), LPSN (-$67M net income, -27.6% margin), ACXP has comparable earnings metrics. Compare ACXP vs PRAX →
ACXP Earnings vs Peers
Earnings metrics vs comparable public companies
ACXP Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$7.97B | -56387.8% | $0 | $-5.32 | - | - |
| 2024 | -$14M | +3.3% | -$14M | $-17.59 | - | - |
| 2023 | -$15M | -20.5% | -$15M | $-23.01 | - | - |
| 2022 | -$12M | +5.1% | -$12M | $-22.36 | - | - |
| 2021 | -$13M | -177.1% | -$13M | $-24.96 | - | - |
| 2020 | -$5M | +22.4% | -$5M | $-9.28 | - | - |
| 2019 | -$6M | - | -$6M | $-12.00 | - | - |
See ACXP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACXP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACXP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACXP — Frequently Asked Questions
Quick answers to the most common questions about buying ACXP stock.
Is ACXP growing earnings?
ACXP EPS is $-5314.57, with earnings growth accelerating to +69.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-8.0B.
What are ACXP's profit margins?
Acurx Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ACXP's earnings?
ACXP earnings data spans 2019-2025. The accelerating earnings trend is +69.8% YoY. Historical data enables comparison across business cycles.